OncLive TV

Hossein Borghaei, DO, MS, discusses emerging biomarkers of response to immunotherapy in non–small cell lung cancer (NSCLC).

Kurt W. Tauer, MD, FACP, discusses the potential implications of biosimilars on cancer research funding.

Sagar Lonial, MD, FACP, discusses treatments for patients with heavily pretreated multiple myeloma.

Miguel-Angel Perales, MD, discusses replacing autologous stem cell transplant with CAR T-cell therapy in diffuse large B-cell lymphoma.

Jonathon B. Cohen, MD, MS, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

A. Oliver Sartor, MD, discusses the phase III VISION trial in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Manuel Hidalgo Medina, MD, PhD, discusses the emergence of neoadjuvant chemotherapy and radiation in pancreatic cancer.

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the FDA approval of zanubrutinib (Brukinsa) in mantle cell lymphoma (MCL).

Gregory Vidal, MD, PhD, discusses the potential of [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.

Benjamin P. Levy, MD, discusses the identification of molecular drivers in non–small cell lung cancer.

Christine Bestvina, MD, discusses the phase III KEYNOTE-407 trial in squamous non–small cell lung cancer.

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses methods of evaluating measurable residual disease (MRD) in multiple myeloma.

Charles A. Leath III, MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses agents under investigation in cervical cancer.

Bradley G. Somer, MD, associate professor, Department of Hematology and Medical Oncology, University of Tennessee Health Science Center, medical oncologist, senior partner, Executive Cancer Council, and head of strategic expansion/development, West Cancer Center Research Program, West Cancer Center, explains where the hesitancy regarding biosimilar use in oncology.

Lee S. Schwartzberg, MD, FACP, explains how biosimilars could lead to increased competition in oncology.

Robert L. Coleman, MD, FACOG, FACS, discusses ongoing research efforts in cervical cancer.

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma who have brain metastases.

Mary J. Fidler, MD, discusses the results of the phase III RELAY trial in treatment-naïve patients with EGFR-mutant non–small cell lung cancer.

Ajay K. Nooka, MD, MPH, FACP, discusses current options for transplant-eligible and -ineligible patients with multiple myeloma.

Carlos E. Vargas, MD, discusses toxicities associated with stereotactic body radiation therapy compared with standard fractionated radiation therapy in prostate cancer.

Simon Rule, MD, PhD, discusses what the treatment landscape of mantle cell lymphoma may look like in the next decade.

Mark G. Kris, MD, discusses the ongoing search for additional biomarkers in advanced squamous non­–small cell lung cancer.

Ivan M. Borrello, MD, discusses treatment for patients with indolent versus aggressive relapsed multiple myeloma.

Keerthi Gogineni, MD, MSHP, discusses the clinical implications of the phase II APT trial in HER2-positive breast cancer.

Allyson Ocean, MD, discusses efforts to improve early detection rates in pancreatic cancer.

Floor J. Backes, MD, discusses the safety profile from a phase I study looking at lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Erika P. Hamilton, MD, discusses the impact of biosimilars in oncology.

Eric Jonasch, MD, discusses how to modulate the tumor microenvironment in renal cell carcinoma.

Ghanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.